Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other financing activities (2016 - 2020)

Historic Other financing activities for Agios Pharmaceuticals (AGIO) over the last 5 years, with Q2 2020 value amounting to $250.5 million.

  • Agios Pharmaceuticals' Other financing activities changed N/A to $250.5 million in Q2 2020 from the same period last year, while for Mar 2021 it was $250.5 million, marking a year-over-year change of. This contributed to the annual value of $250.5 million for FY2020, which is N/A changed from last year.
  • Per Agios Pharmaceuticals' latest filing, its Other financing activities stood at $250.5 million for Q2 2020.
  • Over the past 5 years, Agios Pharmaceuticals' Other financing activities peaked at $250.5 million during Q2 2020, and registered a low of -$727000.0 during Q4 2017.
  • Moreover, its 4-year median value for Other financing activities was $124000.0 (2016), whereas its average is $27.8 million.
  • In the last 5 years, Agios Pharmaceuticals' Other financing activities plummeted by 78584.91% in 2017 and then soared by 19950.98% in 2018.
  • Quarter analysis of 4 years shows Agios Pharmaceuticals' Other financing activities stood at $106000.0 in 2016, then crashed by 785.85% to -$727000.0 in 2017, then surged by 127.92% to $203000.0 in 2018, then soared by 123317.24% to $250.5 million in 2020.
  • Its Other financing activities was $250.5 million in Q2 2020, compared to $203000.0 in Q2 2018 and $188000.0 in Q1 2018.